Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Gyre Therapeutics to post earnings of $0.04 per share and revenue of $23.50 million for the quarter.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. The firm had revenue of $27.87 million during the quarter, compared to analyst estimates of $23.50 million.
Gyre Therapeutics Stock Down 5.0 %
GYRE traded down $0.52 during trading on Friday, reaching $9.70. 143,509 shares of the company's stock were exchanged, compared to its average volume of 80,987. The business has a 50 day moving average price of $11.31 and a 200 day moving average price of $12.23. Gyre Therapeutics has a fifty-two week low of $8.26 and a fifty-two week high of $19.00.
Wall Street Analyst Weigh In
Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.
View Our Latest Stock Report on Gyre Therapeutics
Insider Buying and Selling at Gyre Therapeutics
In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares of the company's stock, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 36,054 shares of company stock valued at $411,597. 19.52% of the stock is currently owned by corporate insiders.
Institutional Trading of Gyre Therapeutics
A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE lifted its position in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,937 shares of the company's stock after purchasing an additional 1,996 shares during the quarter. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. 23.99% of the stock is owned by hedge funds and other institutional investors.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
